Corporate Profile

The cancer treatment paradigm has shifted dramatically, providing evidence that the immune system can be educated to recognize and eliminate the patient’s tumor cells. At Candel Therapeutics, we are developing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor antigens and neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor through in situ vaccination, with the potential to change disease outcomes across a variety of indications. Candel’s product candidates are designed to improve survival while maintaining quality of life in patients with early- to late-stage disease.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description Form

Report of unscheduled material events or corporate event

8-K

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A

An annual report to security holders

ARS